Sandoz, the generic arm of Swiss drug maker Novartis, recently closed its facility developing active pharmaceutical ingredients (API) near Mumbai, a person close to the development told Business Standard. This facility was part of the company’s global development centre in India. Novartis confirmed the move. In response to an e-mail query, Novartis India Vice-Chairman & Managing Director Ranjit Shahani said, “The decision was taken as part of a project portfolio optimisation within Sandoz Global Development.”
